[1] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. doi:10.3322/caac.21551.
|
[2] |
GUPTA K K, GUPTA V K, NAUMANN R W. Ovarian cancer:screening and future directions[J]. Int J Gynecol Cancer, 2019, 29(1):195-200. doi:10.1136/ijgc-2018-000016.
|
[3] |
杨维娜, 徐燕颖. 长链非编码RNA在卵巢癌中的研究进展[J]. 山东医药, 2020, 60(29):91-93.
|
|
YANG W N, XU Y Y. Research progress of long chain noncoding RNA in ovarian cancer[J]. Shandong Med J, 2020, 60(29):91-93. doi:10.3969/j.issn.1002-266X.2020.29.027.
|
[4] |
MACDONALD W A, MANN M R W. Long noncoding RNA functionality in imprinted domain regulation[J]. PLoS Genet, 2020, 16(8):e1008930. doi:10.1371/journal.pgen.1008930.
|
[5] |
ZHANG X, ZHAO X, LI Y, et al. Long noncoding RNA SOX21-AS1 promotes cervical cancer progression by competitively sponging miR-7/VDAC1[J]. J Cell Physiol, 2019, 234(10):17494-17504. doi:10.1002/jcp.28371.
|
[6] |
SHENG X Y, WANG C H, WANG C F, et al. Long-chain non-coding SOX21-AS1 promotes proliferation and migration of breast cancer cells through the PI3K/AKT signaling pathway[J]. Cancer Manag Res, 2020, 12(11):11005-11014. doi:10.2147/CMAR.S270464.
|
[7] |
武金玉, 张苑珑, 黄明莉, 等. Wnt/β-catenin通路在卵巢癌中的调控机制研究进展[J]. 现代妇产科进展, 2018, 27(4):311-313,317.
|
|
WU J Y, ZHANG Y L, HUANG M L, et al. Research progress on the regulatory mechanism of Wnt/β-catenin pathway in ovarian cancer[J]. Prog Obstet Gyne, 2018, 27(4):311-313,317. doi:10.13283/j.cnki.xdfckjz.2018.04.016.
|
[8] |
GAI S Y, YUAN Z H. Long non-coding RNA SOX21-AS1 promotes cell proliferation and invasion through upregulating PAK7 expression by sponging miR-144-3p in glioma cells[J]. Neoplasma, 2020, 67(2):333-343. doi:10.4149/neo_2020_190509N412.
|
[9] |
WANG J Y, LU A Q, CHEN L J. LncRNAs in ovarian cancer[J]. Clin Chim Acta, 2019, 90(5):17-27. doi:10.1016/j.cca.2018.12.013.
|
[10] |
MORAND S, DEVANABOYINA M, STAATS H, et al. Ovarian cancer immunotherapy and personalized medicine[J]. Int J Mol Sci, 2021, 22(12):6532. doi:10.3390/ijms22126532.
|
[11] |
LIM S M, SYN N L, CHO B C, et al. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer:Mechanisms and therapeutic strategies[J]. Cancer Treat Rev, 2018, 65(8):1-10. doi:10.1016/j.ctrv.2018.02.006.
|
[12] |
SAKACH E, O'REGAN R, MEISEL J, et al. Molecular classification of triple negative breast cancer and the emergence of targeted therapies[J]. Clin Breast Cancer, 2021, 21(6):509-520. doi:10.1016/j.clbc.2021.09.003.
|
[13] |
BARTOLETTI M, PELIZZARI G, GERRATANA L, et al. Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer:a network Meta-analysis[J]. Int J Mol Sci, 2020, 21(11):3805. doi:10.3390/ijms21113805.
|
[14] |
LIU X, SONG J, KANG Y, et al. Long noncoding RNA SOX21-AS1 regulates the progression of triple-negative breast cancer through regulation of miR-520a-5p/ORMDL3 axis[J]. J Cell Biochem, 2020, 121(11):4601-4611. doi:10.1002/jcb.29674.
|
[15] |
ZHANG L, FANG Y, CHENG X, et al. Silencing of long noncoding RNA SOX21-AS1 relieves neuronal oxidative stress injury in mice with alzheimer's disease by upregulating FZD3/5 via the Wnt signaling pathway[J]. Mol Neurobiol, 2019, 56(5):3522-3537. doi:10.1007/s12035-018-1299-y.
|
[16] |
WEI C, WANG H, XU F, et al. LncRNA SOX21-AS1 is associated with progression of hepatocellular carcinoma and predicts prognosis through epigenetically silencing p21[J]. Biomed Pharmacother, 2018, 104(8):137-144. doi:10.1016/j.biopha.2018.05.010.
|
[17] |
ZHANG J, HOU T, QI X, et al. SOX21-AS1 is associated with clinical stage and regulates cell proliferation in nephroblastoma[J]. Biosci Rep, 2019, 39(5):BSR20190602. doi:10.1042/BSR20190602.
|
[18] |
CHEN H, CHEN J. LncRNA SOX21-AS1 promotes the growth and invasiveness of osteosarcoma cells through miR-7-5p/IRS2 regulatory network[J]. Arch Med Res, 2021, 52(3):294-303. doi:10.1016/j.arcmed.2020.11.007.
|
[19] |
LI L, MENG D, WANG R. Long non-coding RNA SOX21-AS1 enhances the stemness of breast cancer cells via the Hippo pathway[J]. FEBS Open Bio, 2021, 11(1):251-264. doi:10.1002/2211-5463.13015.
|
[20] |
LECARPENTIER Y, SCHUSSLER O, HÉBERT J L, et al. Multiple targets of the canonical WNT/β-Catenin signaling in cancers[J]. Front Oncol, 2019, 9(11):1248. doi:10.3389/fonc.2019.01248.
|